See more : Mitsubishi Motors Corporation (MMTOF) Income Statement Analysis – Financial Results
Complete financial analysis of Catheter Precision, Inc. (VTAK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Catheter Precision, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Modern Shares & Stockbrokers Limited (MODRNSH.BO) Income Statement Analysis – Financial Results
- Kodiak Sciences Inc. (KOD) Income Statement Analysis – Financial Results
- Spencer’s Retail Limited (SPENCER.BO) Income Statement Analysis – Financial Results
- MSR India Limited (MSRINDIA.BO) Income Statement Analysis – Financial Results
- Zonetail Inc. (ZTLLF) Income Statement Analysis – Financial Results
Catheter Precision, Inc. (VTAK)
About Catheter Precision, Inc.
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 442.00K | 14.00K | 22.00K | 4.41M | 7.20M | 6.26M | 5.87M | 5.98M |
| Cost of Revenue | 30.00K | 161.00K | 1.56M | 5.48M | 8.85M | 4.21M | 4.17M | 3.14M |
| Gross Profit | 412.00K | -147.00K | -1.54M | -1.08M | -1.65M | 2.05M | 1.71M | 2.84M |
| Gross Profit Ratio | 93.21% | -1,050.00% | -6,990.91% | -24.45% | -22.93% | 32.78% | 29.05% | 47.49% |
| Research & Development | 475.00K | 6.39M | 12.25M | 9.01M | 4.53M | 2.78M | 4.52M | 1.72M |
| General & Administrative | 0.00 | 2.23M | 0.00 | 25.97M | 51.55M | 30.44M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.12M | 16.25M | 15.48M | 25.97M | 51.55M | 30.44M | 14.95M | 5.32M |
| Other Expenses | 60.93M | 99.00K | 2.01M | 21.00K | 788.00K | 338.00K | 14.95M | 5.32M |
| Operating Expenses | 78.53M | 22.64M | 27.73M | 34.98M | 56.08M | 33.21M | 19.47M | 7.04M |
| Cost & Expenses | 78.56M | 22.80M | 29.29M | 40.46M | 64.93M | 37.42M | 23.63M | 10.17M |
| Interest Income | 347.00K | 0.00 | 0.00 | 129.00K | 1.04M | 352.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 3.08M | 0.00 | 108.00K | 250.00K | 14.00K | 4.00K | 3.00K |
| Depreciation & Amortization | 2.08M | 421.00K | 1.40M | 2.00M | 1.75M | 624.00K | 218.00K | 95.00K |
| EBITDA | -15.11M | -22.37M | -27.70M | -33.30M | -54.94M | -30.18M | -17.54M | -4.10M |
| EBITDA Ratio | -3,418.55% | -129,971.43% | -133,027.27% | -818.59% | -801.92% | -498.00% | -298.84% | -68.66% |
| Operating Income | -78.12M | -26.96M | -29.27M | -36.06M | -57.73M | -31.16M | -17.76M | -4.20M |
| Operating Income Ratio | -17,673.98% | -192,578.57% | -133,027.27% | -818.59% | -801.92% | -498.00% | -302.56% | -70.25% |
| Total Other Income/Expenses | 7.55M | -4.07M | 2.01M | 88.00K | 788.00K | 338.00K | -4.00K | -3.00K |
| Income Before Tax | -70.57M | -26.86M | -27.26M | -36.04M | -56.94M | -30.82M | -17.76M | -4.20M |
| Income Before Tax Ratio | -15,966.52% | -191,871.43% | -123,895.45% | -818.12% | -790.97% | -492.60% | -302.62% | -70.30% |
| Income Tax Expense | 0.00 | 3.00K | 4.00K | 7.00K | 15.00K | 10.00K | 1.00K | 1.00K |
| Net Income | -70.57M | -26.87M | -25.07M | -36.05M | -56.96M | -30.83M | -17.77M | -4.20M |
| Net Income Ratio | -15,966.52% | -191,892.86% | -113,954.55% | -818.27% | -791.18% | -492.76% | -302.64% | -70.31% |
| EPS | -12.99 | -25.98 | -248.22 | -1.06K | -5.42K | -4.18K | -1.83K | -433.96 |
| EPS Diluted | -12.99 | -25.98 | -248.22 | -1.06K | -5.42K | -4.18K | -1.83K | -433.96 |
| Weighted Avg Shares Out | 5.50M | 1.03M | 101.00K | 33.98K | 10.52K | 7.38K | 9.68K | 9.68K |
| Weighted Avg Shares Out (Dil) | 5.50M | 1.03M | 101.00K | 33.98K | 10.52K | 7.38K | 9.68K | 9.68K |
Catheter Precision, Inc. Expands LockeT Distribution to Middle East
FORT MILL, SC / ACCESSWIRE / September 18, 2024 / Catheter Precision, Inc. (the"Company") (NYSE American:VTAK), a US based medical device pioneering electrophysiology products, announced that it has completed a distribution agreement for LockeT with Dubai based company Forum Medical....
Catheter Precision, Inc. (NYSE American: VTAK) Reports First Purchase Order for LockeT in the Pacific Northwest Territory
FORT MILL, SC / ACCESSWIRE / September 11, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company in the growing field of cardiac electrophysiology, announced its first purchase order from the pacific northwest territory. As...
Presentation at European Society of Cardiology Demonstrates VIVO Accuracy in Complex VT Patients
FORT MILL, SC / ACCESSWIRE / September 5, 2024 / Catheter Precision, Inc. (NYSE American:VTAK) today announced that at the recently held European Society of Cardiology (ESC) Symposium, interim results demonstrating the use of VIVO in localizing the site of...
Catheter Precision, Inc. (NYSE American:VTAK) Reports First Purchase Order for LockeT in a New US Territory
FORT MILL, SC / ACCESSWIRE / September 4, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a MedTech company pioneering products in the growing field of cardiac electrophysiology, announced its first purchase order from a hospital in the greater Chicago area....
Catheter Precision, Inc. Announces Closing of $3.6 Million Underwritten Public Offering and Exercise of Overallotment Option
FORT MILL, SC / ACCESSWIRE / September 3, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company, today announced the closing of its previously announced public offering of 805,900 common stock units, including 458,623 common stock...
Catheter Precision, Inc. Announces Pricing of $3.1 Million Underwritten Public Offering
FORT MILL, SC / ACCESSWIRE / August 30, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company, today announced the pricing of its underwritten public offering of common stock units and pre-funded units for aggregate gross...
Catheter Precision, Inc. (NYSE American: VTAK) Reports Q2 2024 Highlights and Operational Performance Report
FORT MILL, SC / ACCESSWIRE / August 14, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q2 Financials and Operational Report. Operational...
Catheter Precision, Inc. Announces Publication of LockeT Data in the Journal of Cardiovascular Electrophysiology
FORT MILL, SC / ACCESSWIRE / August 6, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today the publication of its first LockeT study in the Journal of Cardiovascular Electrophysiology. The study titled,...
Catheter Precision, Inc. Completes Enrollment of 75 Patients in LockeT-II Study
FORT MILL, SC / ACCESSWIRE / July 25, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today that it has enrolled 75 patients in its Phase II LockeT Study, which is now expected...
Catheter Precision, Inc. Announces the Completion of Patient Follow-up for the VIVO European Registry and New Product Evaluations of VIVO
FORT MILL, SC / ACCESSWIRE / July 16, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today that the patient follow-up phase for the VIVO European Registry has concluded. The EU registry began...
Source: https://incomestatements.info
Category: Stock Reports